Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
Your hard-earned money would be better spent elsewhere.
The Pulse Report highlights AI's expanding role in drug discovery, biomarker identification, clinical trial optimization and ...
The new "Claude Science" from Anthropic uses artificial intelligence to tackle rare genetic disorders and tropical maladies, ...
Chai Discovery's $400M Series C triples its value to $3.8bn, a fresh sign that AI drug discovery has moved from promise to deployment at big pharma.
Anthropic's Claude Science integrates 60+ scientific databases into a single AI workbench. What it means for biotech and life ...
Superintelligence is not one event — it is and will be a frontier that advances domain by domain, in strict order of how ...
Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies ...
Transformer on MSN
A data bottleneck could slow the superintelligence race
And that could be a good thing ...
When researchers screen potential tuberculosis drugs, they often end up with too many options. Some look promising but later ...
The results of a recent AI competition show that better data trumps bigger models when it comes to predicting properties of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results